Scarica l'app Stockscreener
25.15
3.12%
-0.81
Dopo l'orario di chiusura:
25.15
Zymeworks Inc. Borsa (ZYME) Ultime notizie
EBIT per share of Zymeworks Inc. – HAN:ZA8 - TradingView
Zymeworks stock coverage reinstated at Buy by TD Cowen on acquisition - Investing.com Nigeria
Citigroup keeps 'Buy' on Zymeworks after acquis... - Pluang
Zymeworks Inc. (ZYME) Stock Price, News, Quote & History - Yahoo! Finance Canada
Zymeworks Inc. (ZYME) stock price, news, quote and history - uk.finance.yahoo.com
Zymeworks (ZYME) Completes Theravance Biopharma Acquisition, Eyes Growth in COPD Market - GuruFocus
Zymeworks Updates Annual Financial Targets After Finalizing Theravance Biopharma Deal - TradingView
Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition - wahanariau.com
Zymeworks Completes Theravance Acquisition Deal - grafa.com
Zymeworks Inc. Updates Earnings Guidance for the Year 2026 - marketscreener.com
Zymeworks Inc. (ZYME) Theravance Biopharma, Inc.M&A CallSlideshow (NASDAQ:ZYME) 2026-09-28 - Seeking Alpha
Zymeworks Inc Expects Total Revenue, Including Collaboration Revenue From Yupelri, For 2026 To Be Between $278 Million And $292 Million - TradingView
Zymeworks Announces Updated 2026 Financial Guidance and - GlobeNewswire
Bank of America Corp DE Buys 219,071 Shares of Zymeworks Inc. $ZYME - MarketBeat
Theravance Biopharma Insider Brett Grimaud Reports Complete Share Cancellation Following Zymeworks Merger - Kalkine Media
Vancouver biotech Zymeworks closes US$929M Theravance deal - Business in Vancouver
Zymeworks closes out acquisition of Theravance for USD 929m - AllSci
What Does the Theravance Acquisition Add for Zymeworks (NASDAQ:ZYME)? - Kalkine Media
Zymeworks Completes Acquisition of Theravance Biopharma - Indovizka.com
Zymeworks Finalizes Merger with Theravance Biopharma and Launches $350M Senior Secured Notes - Kalkine Media
Zymeworks completes acquisition of Theravance Biopharma By Investing.com - Investing.com Australia
Zymeworks completes acquisition of Theravance Biopharma - Investing.com
Zymeworks Raises $350 Million Notes and Launches Ampreloxetine CVR - TradingView
A $350 million debt issue helped fund Zymeworks (ZYME)'s Theravance acquisition, with cash due per eligible share. - Stock Titan
Squarepoint Ops LLC Reduces Holdings in Zymeworks Inc. $ZYME - MarketBeat
Zymeworks stock gains on fresh Wolfe Research coverage - AD HOC NEWS
Zymeworks stock gains on merger approval and a $41 target - AD HOC NEWS
Zymeworks Inc. (NASDAQ:ZYME) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Theravance Biopharma shareholders approve merger with Zymeworks By Investing.com - Investing.com India
Theravance Biopharma Shareholders Endorse Merger with Zymeworks Inc. - kalkinemedia.com
Zymeworks Stock Price Forecast. Should You Buy ZYME? - StockInvest.us
Theravance Biopharma shareholders approve merger with Zymeworks - Investing.com
Zymeworks' Theravance Deal Is A Breath Of Fresh Cash Flow (NASDAQ:ZYME) - Seeking Alpha
Zymeworks stock gains as Theravance deal and valuation draw investor focus - AD HOC NEWS
Zymeworks Inc. (ZYME): Investor Outlook Reveals 50% Upside Potential In Biotech Arena - DirectorsTalk Interviews
Why Is Wolfe Research Starting Coverage On Zymeworks (NASDAQ:ZYME)? - Kalkine Media
Wolfe Research Begins Coverage on Zymeworks (NASDAQ:ZYME) - MarketBeat
Zymeworks Inc. at Morgan Stanley Global Healthcare Conference Transcript - GuruFocus
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 238,026 Shares of Zymeworks Inc. $ZYME - MarketBeat
Wellington Management Group LLP Takes $2.88 Million Position in Zymeworks Inc. $ZYME - MarketBeat
Legal & General Group Plc Makes New $1.13 Million Investment in Zymeworks Inc. $ZYME - MarketBeat
Bank of New York Mellon Corp Acquires New Holdings in Zymeworks Inc. $ZYME - MarketBeat
JPMorgan Chase & Co. Boosts Zymeworks (NASDAQ:ZYME) Price Target to $33.00 - MarketBeat
Zymeworks (ZYME) Falls 3.7% to $29.9 as Shares Slip Below $30RVOL Breakout - careplusvn.com
Zymeworks (NASDAQ:ZYME) Hits New 1-Year HighTime to Buy? - MarketBeat
Zymeworks stock hits 52-week high at 30.75 USD - Investing.com
Zymeworks stock hits 52-week high at 30.75 USD By Investing.com - Investing.com Nigeria
ZJM stock holds near its latest trade. Zymeworks data still drives the setup - AD HOC NEWS
Zymeworks options signal bullish surge as $35 September calls dominate - Investing.com
Enterprise value to revenue forward of Zymeworks Inc. – NASDAQ:ZYME - TradingView
Man Group plc Invests $5.51 Million in Zymeworks Inc. $ZYME - marketbeat.com
4,251,030 Shares in Zymeworks Inc. $ZYME Bought by BlackRock Inc. - marketbeat.com
Zymeworks stock holds near $28.27 as market cap tops $2.01 billion - ad-hoc-news.de
FY2026 EPS Estimates for Zymeworks Raised by HC Wainwright - MarketBeat
Zymeworks (ZYME), What Is Behind The Renewed Attention? - Yahoo Finance
Zymeworks shifts to revenue growth after FDA ap... - Pluang
HC Wainwright Has Strong Estimate for Zymeworks Q3 Earnings - marketbeat.com
Zymeworks: Transitioning Into A Royalty-Driven Biopharma Platform Post Ziihera Approval - Seeking Alpha
Zymeworks moves higher as Street cheers Ziihera regimen approval - Seeking Alpha
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):